When was 1910 Genetics founded?

1910 Genetics was founded in 2018.

Where is 1910 Genetics located?

1910 Genetics is headquartered in Cambridge, United States.

Who is the current CEO of 1910 Genetics?

Jen Nwankwo of 1910 Genetics. They have also founded 1 company.

How many employees does 1910 Genetics have?

As of May 31, 2026, the latest employee count at 1910 Genetics is 45.

Is 1910 Genetics a funded company?

1910 Genetics is a funded company, having raised a total of $29.8M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of 1910 Genetics?

1910 Genetics' latest funding was a $***** Series A round on Oct 31, 2024, with participation from 1 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.88B in funding in 2026 to date.

Where does 1910 Genetics rank among its competitors?

1910 Genetics ranks 55th amongst 270 active competitors, of which 83 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tandem AI, which secured $22M in Nov, 2025.

Who are the top competitors of 1910 Genetics?

1910 Genetics' top competitors include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Among them, Tandem AI secured the most recent funding round in November, 2025.

1910 Genetics - 2026 Company Profile, Team, Funding & Competitors

1910 Genetics is a series A company based in Cambridge (United States), founded in 2018 by Jen Nwankwo. It operates as a Developer of small molecule therapeutics to treat pain and aging-related diseases. 1910 Genetics has raised $29.8M in funding from Y Combinator and M12. The company has 270 active competitors, including 83 funded and 15 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics.

Company Details

Developer of small molecule therapeutics to treat pain and aging-related diseases. It is a biotechnology company that integrates AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics. The company have developed two discovery engines ELVIS and ROSALYND that enable to design drug candidates.

Website: www.1910genetics.com
Email ID: *****@1910genetics.com

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Series A

Total Funding

$29.8M in 5 rounds

Latest Funding Round

Series A, Oct 31, 2024, $*****

Investors

Y Combinator & 12 more

Ranked

55^th among 270 active competitors

Employee Count

45 as on May 31, 2026

Similar Companies

OpenEvidence & 3063 more

View 1910 Genetics' full profile

1910 Genetics has raised a total funding of $29.8M over 5 rounds. Its latest funding round was a Series A round on Oct 31, 2024 for $*****. 1 investor participated in its latest round. 1910 Genetics has 11 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of 1910 Genetics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2024	5109080	Series A	7041137	7673700	3739855	4847017
Sep 30, 2021	8664997	Grant (prize money)	7878908	4469055	5417934	NIH
Jul 01, 2021	7604877	Grant (prize money)	9029454	5456368	4130901	HHS

Access funding benchmarks and valuations. Sign up today!

View details of 1910 Genetics's funding rounds and investors

The founders of 1910 Genetics is Jen Nwankwo. Jen Nwankwo is the CEO of 1910 Genetics.

Here are the details of 1910 Genetics' key team members:

Jen Nwankwo: Founder & CEO of 1910 Genetics.
Contact Info: 1 email address

View details of 1910 Genetics's Founder profiles and Board Members

1910 Genetics' employee count trend

1910 Genetics has 45 employees as of May 26. Here is 1910 Genetics's employee count trend over the years:

Uncover 1910 Genetics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 1910 Genetics include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Here is the list of Top 10 competitors of 1910 Genetics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 48 others	72/100
3rd	Relay Therapeutics 2016, Cambridge (United States), Public	Developer of drug discovery platform and study protein motion	$520M	BVF Partners, SoftBank Vision Fund & 17 others	70/100
4th	Atomwise 2012, San Francisco (United States), Series B	Developer of artificial intelligence platform for small molecule drug discovery	$219M	DCVC, B Capital & 27 others	67/100
5th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	67/100
6th	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Orbimed & 25 others	67/100
7th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
8th	In Silico 2014, Boston (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Value Partners & 36 others	63/100
9th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, R42 Group & 19 others	62/100
55th	1910 Genetics 2018, Cambridge (United States), Series A	Developer of small molecule therapeutics to treat pain and aging-related diseases	$29.8M	Point Reyes Management, New Ventures Funds ... & 11 others	44/100